Division of Cardiology Department of Internal Medicine Severance Cardiovascular HospitalYonsei University College of Medicine Seoul Korea.
Department of Cardiology CHA Bundang Medical CenterCHA University Seongnam Korea.
J Am Heart Assoc. 2021 Dec 21;10(24):e023055. doi: 10.1161/JAHA.121.023055. Epub 2021 Dec 10.
Background Rhythm control is associated with better cardiovascular outcomes than usual care among patients with recently diagnosed atrial fibrillation (AF). This study investigated the effects of rhythm control compared with rate control on the incidence of stroke, heart failure, myocardial infarction, and cardiovascular death stratified by timing of treatment initiation. Methods and Results We conducted a retrospective population-based cohort study including 22 635 patients with AF newly treated with rhythm control (antiarrhythmic drugs or ablation) or rate control in 2011 to 2015 from the Korean National Health Insurance Service database. Propensity overlap weighting was used. Compared with rate control, rhythm control initiated within 1 year of AF diagnosis decreased the risk of stroke. The point estimates for rhythm control initiated at selected time points after AF diagnosis are as follows: 6 months (hazard ratio [HR], 0.76; 95% CI, 0.66-0.87), 1 year (HR, 0.78; 95% CI, 0.66-0.93), and 5 years (HR, 1.00; 95% CI, 0.45-2.24). The initiation of rhythm control within 6 months of AF diagnosis reduced the risk of hospitalization for heart failure: 6 months (HR, 0.84; 95% CI, 0.74-0.95), 1 year (HR, 0.96; 95% CI, 0.82-1.13), and 5 years (HR, 2.88; 95% CI, 1.34-6.17). The risks of myocardial infarction and cardiovascular death did not differ between rhythm and rate control regardless of treatment timing. Conclusions Early initiation of rhythm control was associated with a lower risk of stroke and heart failure-related admission than rate control in patients with recently diagnosed AF. The effects were attenuated as initiating the rhythm control treatment later.
与常规治疗相比,节律控制可改善近期诊断为心房颤动(房颤)患者的心血管结局。本研究旨在探讨节律控制与心率控制在治疗起始时机分层下对卒中、心力衰竭、心肌梗死和心血管死亡发生率的影响。
我们开展了一项回顾性基于人群的队列研究,纳入了 2011 年至 2015 年期间韩国国家健康保险服务数据库中 22635 例接受节律控制(抗心律失常药物或消融术)或心率控制治疗的新发房颤患者。采用倾向重叠加权法。与心率控制相比,房颤诊断后 1 年内开始节律控制可降低卒中风险。房颤诊断后选择时间点开始节律控制的点估计值如下:6 个月(风险比[HR],0.76;95%CI,0.66-0.87)、1 年(HR,0.78;95%CI,0.66-0.93)和 5 年(HR,1.00;95%CI,0.45-2.24)。房颤诊断后 6 个月内开始节律控制可降低心力衰竭住院风险:6 个月(HR,0.84;95%CI,0.74-0.95)、1 年(HR,0.96;95%CI,0.82-1.13)和 5 年(HR,2.88;95%CI,1.34-6.17)。无论治疗时机如何,节律控制与心率控制之间的心肌梗死和心血管死亡风险均无差异。
与心率控制相比,近期诊断为房颤的患者早期开始节律控制可降低卒中风险和心力衰竭相关住院风险。随着节律控制治疗开始时间的推迟,这种效果减弱。